Pharmacokinetics and plasma protein binding of a single dose of clodronate disodium are similar for juvenile sheep and horses.

The study examines the pharmacokinetics, the study of how a drug moves within a body, of a single dose of clodronate disodium in young sheep, as well as how it binds with proteins in the plasma in both young sheep and horses.

Objective and Methodology of the Study

• The goal was to understand how a single dose of clodronate disodium (also known as CLO), a medication often used to manage bone-related diseases, behaves in the body of young crossbred sheep.
• Another aim was to study how this drug binds with proteins in the blood plasma (plasma protein binding or PPB) of both young sheep and horses.
• For the study, a total of 14 sheep were monitored, alongside 3 young quarter horses for the PPB analysis.
• They utilized liquid chromatography-mass spectrometry to determine CLO concentrations.
• The pharmacokinetic parameters were calculated by examining plasma samples taken at intervals of up to 72 hours after administration of the medication.
• PPB was checked using the plasma of horses and sheep in a rapid equilibrium dialysis system.

Results

• The study found that key parameters such as maximum plasma concentration, time of maximal concentration, and area under the curve (AUC), were similar to values previously reported in horses.
• PPB in sheep and horses was found to be moderate to high, with the unbound fraction being slightly higher in sheep than in horses. However, the difference was less than 1.4-fold.

Conclusion

• The research concluded that the behavior and effects of CLO in young sheep were similar to those seen in horses.
• This suggests that researchers could use juvenile sheep as an animal model to study risks and benefits of bisphosphonate use. This is particularly helpful for research related to how these drugs behave in young horses, potentially contributing to better veterinary care for these animals.